HELSINKI, November 13, 2018. Aplagon Oy (“Aplagon”), today announced that patent, “Therapeutic APAC Molecule Comprising Heparin Conjugated to a Plasma Protein” has been granted by the European Patent Office (patent number EP 3185907 (A1)) and the Companies and Intellectual Property Commission of South Africa (patent number 2017/00701).
The claims of the patent cover the composition of APACs, their use as a medicine and therapeutic applications as well as a method for their production.

Aki Prihti, CEO of Aplagon, said: “This new protection strengthens our patent family and protects the IP closest to our pipeline. It is great to have been granted protection in both Europe and South Africa and we are now looking to expand our protection into other territories within the coming months.”

Aplagon is developing APACs, first-in-class antithrombotics, for the prevention and treatment of blood vessel occlusions related to vascular interventions. While APACs are named after their unique dual antiplatelet (AP) and anticoagulant (AC) activity, they can also target and act locally at the vascular injury site thereby reducing the bleeding risks associated with systemic antithrombotics. Furthermore, APACs can address both the short- and long- term complications of vascular interventions, i.e. acute clot (thrombus) formation and later vascular wall thickening and narrowing of the vessel lumen, which lead to blood clots or thrombotic occlusions.

– Ends –

About Aplagon Oy (www.aplagon.com )
Aplagon Oy is a pharmaceutical discovery and development company, based in Helsinki, Finland, developing proprietary locally acting antithrombotic products (APACs) for the management of vascular intervention-related blood vessel occlusions.

The Company has a strong network of collaborators among top scientists and laboratories in Europe and the US in the field of vascular medicine. It is backed by leading Finnish life science investors: Innovestor Ventures; Jenny and Antti Wihuri Foundation; and Helsinki University Funds.

Aplagon was founded in 2009 and is based on the pioneering research performed by Prof. Riitta Lassila and associates at Wihuri Research Institute in Helsinki, Finland on mast cell-derived heparin proteoglycans. Aplagon owns all Intellectual Property rights to the APAC molecule.

Aplagon Oy

At the Company: Aki Prihti, CEO Tel. +358-40-762 5159 aki.prihti@aplagon.com

Media enquiries: Sue Charles/ Eileen Paul/Gemma Harris Instinctif Partners Tel: +44 20 7866 7860 aplagon@instinctif.com